OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany. METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005. 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival. RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females. There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality. The median follow-up time of patients alive was 42 months. The 5-year overall survival rate (OS) for all patients was 47.8%. The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively. The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001). Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively). Comparing the periods 1996-2000 with the period 2001-2005, there was no significant improvement of OS for any subsite. CONCLUSIONS: Many subsites of head and neck cancer have changing incidence. Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany. METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005. 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival. RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females. There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality. The median follow-up time of patients alive was 42 months. The 5-year overall survival rate (OS) for all patients was 47.8%. The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively. The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001). Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively). Comparing the periods 1996-2000 with the period 2001-2005, there was no significant improvement of OS for any subsite. CONCLUSIONS: Many subsites of head and neck cancer have changing incidence. Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: A Blythe Ryerson; Edward S Peters; Steven S Coughlin; Vivien W Chen; Maura L Gillison; Marsha E Reichman; Xiaocheng Wu; Anil K Chaturvedi; Kelly Kawaoka Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Henry Völzke; Hanne Neuhauser; Susanne Moebus; Jens Baumert; Klaus Berger; Andreas Stang; Ute Ellert; André Werner; Angela Döring Journal: BMC Public Health Date: 2006-06-06 Impact factor: 3.295
Authors: Katrin Hertrampf; Jörg Wiltfang; Alexander Katalinic; Olaf Timm; Hans-Jürgen Wenz Journal: J Cancer Res Clin Oncol Date: 2011-12-14 Impact factor: 4.553
Authors: M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann Journal: HNO Date: 2016-07 Impact factor: 1.284
Authors: Leni Verônica de Oliveira Silva; José Alcides Almeida de Arruda; Lucas Guimarães Abreu; Raquel Conceição Ferreira; Leorik Pereira da Silva; Cibele Pelissari; Ricardo Natã Fonseca Silva; Kaio Heide Sampaio Nóbrega; Bruno Augusto Benevenuto de Andrade; Mario José Romañach; Michelle Agostini; Cassiano Francisco Weege Nonaka; Pollianna Muniz Alves; Hélder Antônio Rebelo Pontes; Luís Fernando Rivero; Lélia Batista de Souza; Marília Trierveiler; Elismauro Francisco Mendonça; Ana Paula Neutzling Gomes; Manoela Domingues Martins; Emanuel Sávio de Souza Andrade; Marcia Maria Fonseca da Silveira; Ana Paula Veras Sobral; Ricardo Alves Mesquita Journal: Head Neck Pathol Date: 2020-02-19
Authors: S Partovi; A Kohan; J L Vercher-Conejero; C Rubbert; S Margevicius; M D Schluchter; C Gaeta; P Faulhaber; M R Robbin Journal: AJNR Am J Neuroradiol Date: 2014-06-12 Impact factor: 3.825
Authors: K Moeller; D Esser; D Boeger; J Buentzel; K Hoffmann; P Jecker; A Mueller; G Radtke; J-U Piesold; S Schultze-Mosgau; M Finkensieper; T Bitter; O Guntinas-Lichius Journal: Eur Arch Otorhinolaryngol Date: 2012-10-17 Impact factor: 2.503
Authors: Dana M Hartl; Daniel F Brasnu; Jatin P Shah; Michael L Hinni; Robert P Takes; Kerry D Olsen; Luiz P Kowalski; Juan P Rodrigo; Primož Strojan; Gregory T Wolf; Alessandra Rinaldo; Carlos Suárez; William M Mendenhall; Vinidh Paleri; Arlene A Forastiere; Jochen A Werner; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-01-03 Impact factor: 2.503